SCHEMBL6773702

SCHEMBL6773702

COc1ccc(Br)cc1C(N)CC(=O)O

nearest known ligand 0.47

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
▸ ALDH1A1 P00352 4/20 0.43
▸ KDM4E B2RXH2 3/20 0.43
▸ SMN1; SMN2 Q16637 2/20 0.43
▸ MAPT P10636 1/20 0.43
▸ CASP3 P42574 4/20 0.42
▸ CASP8 Q14790 4/20 0.42
▸ CASP7 P55210 3/20 0.42
▸ TDP1 Q9NUW8 1/20 0.42
▸ PTGFR P43088 3/20 0.42
▸ CTSA P10619 1/20 0.42
▸ MEN1 O00255 1/20 0.42
▸ KMT2A Q03164 1/20 0.42
▸ CASP1 P29466 2/20 0.42
▸ FFAR1 O14842 1/20 0.41
▸ PTGDR2 Q9Y5Y4 1/20 0.41
▸ CYP1A2 P05177 1/20 0.41
▸ CYP2C9 P11712 1/20 0.41
▸ CYP2C19 P33261 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL20855843 0.87 KDM4E (0.45) ALDH1A1KDM4ESMN1; SMN2MAPTTDP1
SCHEMBL7347046 0.85 ALDH1A1 (0.42) ALDH1A1KDM4EMEN1KMT2ACYP1A2
SCHEMBL17755382 0.84 KDM4E (0.46) ALDH1A1KDM4ESMN1; SMN2MAPTCASP3
SCHEMBL5368221 0.84 ADRA1A (0.56) MAPTCTSAMEN1KMT2ACYP1A2
SCHEMBL20855727 0.82 CTSA (0.49) CTSA
SCHEMBL20546455 0.80 CTSA (0.59) CTSAFFAR1
SCHEMBL20546453 0.80 CTSA (0.59) CTSAFFAR1
SCHEMBL12463681 0.80 POLB (0.55) SMN1; SMN2CTSAKMT2A
SCHEMBL3385975 0.80 POLB (0.55) SMN1; SMN2CTSAKMT2A
SCHEMBL5720914 0.80 POLB (0.55) SMN1; SMN2CTSAKMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2019063748-A1 ROR-GAMMA INHIBITORS GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) 2019-04-04 — — WO disclosed
US-6831199-B1 In order to avoid bleeding side-effects when treating the conditions associated with integrin alpha v beta 3, it is beneficial to have compounds which are selective antagonists for alpha v beta 3 versus alpha IIb beta 3 G. D. SEARLE & CO. 2004-12-14 — — US disclosed
EP-0850221-B1 META-GUANIDINE, UREA, THIOUREA OR AZACYCLIC AMINO BENZOIC ACID DERIVATIVES AS INTEGRIN ANTAGONISTS SEARLE & CO (US) 2001-07-18 — — EP disclosed
US-6028223-A AN INTEGRIN ANTAGONISTS TREATING BONE DISORDER, PERIODONTAL DISEASE, OSTEOPOROSIS, HUMORAL HYPERCALCEMIA OF MALIGNANCY, PAGET'S DISEASE, TUMOR ANGIOGENESIS, DIABETIC RETINOPATHY, ARTHRITIS, SMOOTH MUSCLE CELL MIGRATION AND RESTENOSIS G. D. SEARLE & CO. (US) 2000-02-22 — — US disclosed
EP-0850221-A1 META-GUANIDINE, UREA, THIOUREA OR AZACYCLIC AMINO BENZOIC ACID DERIVATIVES AS INTEGRIN ANTAGONISTS G.D. SEARLE & CO. (US) 1998-07-01 — — EP disclosed
WO-1997008145-A1 META-GUANIDINE, UREA, THIOUREA OR AZACYCLIC AMINO BENZOIC ACID DERIVATIVES AS INTEGRIN ANTAGONISTS G.D. SEARLE & CO. (US) 1997-03-06 — — WO disclosed
Send feedback